Variant report
Variant | nsv980643 |
---|---|
Chromosome Location | chr5:53025294-53055999 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:0)
- CpG islands (count:0)
- Chromatin interactive region (count:5)
- LncRNA region (count:0)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
No data |
No data |
(count:5 , 50 per page) page:
1
No. | Distal block | Cell Line | Cell type | Cell Stage |
---|---|---|---|---|
1 | chr5:52777916..52780456-chr5:53034020..53036335,2 | MCF-7 | breast: | |
2 | chr5:53029523..53030741-chr5:53166540..53167569,3 | MCF-7 | breast: | |
3 | chr5:53029076..53030387-chr5:53166234..53167555,10 | MCF-7 | breast: | |
4 | chr5:53038002..53040477-chr5:53041042..53043406,2 | MCF-7 | breast: | |
5 | chr5:53038002..53040477-chr5:53041042..53043406,2 | MCF-7 | breast: |
No data |
No data |
No data |
Variant related genes | Relation type |
---|---|
ENSG00000134363 | chromatin interactions |
No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs550646615 | chr5:53026202-53026203 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
2 | rs113622281 | chr5:53026212-53026213 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
3 | rs545859389 | chr5:53026224-53026225 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
4 | rs72757303 | chr5:53026244-53026245 | Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
5 | rs539477504 | chr5:53026270-53026271 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
6 | rs145510088 | chr5:53026271-53026272 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
7 | rs566799767 | chr5:53026283-53026284 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
8 | rs577064426 | chr5:53026294-53026295 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
9 | rs147720225 | chr5:53026312-53026313 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
10 | rs555552341 | chr5:53026378-53026379 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
11 | rs557411815 | chr5:53026419-53026420 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
12 | rs200232772 | chr5:53026425-53026426 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
13 | rs538341781 | chr5:53026435-53026436 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
14 | rs556287080 | chr5:53026457-53026458 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
15 | rs72757304 | chr5:53026482-53026483 | Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
16 | rs543993456 | chr5:53026534-53026535 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
17 | rs173905 | chr5:53026535-53026536 | Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
18 | rs111589224 | chr5:53026548-53026549 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
19 | rs560094957 | chr5:53026604-53026605 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
20 | rs182486420 | chr5:53026617-53026618 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
21 | rs140988889 | chr5:53026665-53026666 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
22 | rs561533721 | chr5:53026678-53026679 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
23 | rs531855416 | chr5:53026683-53026684 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
24 | rs550385367 | chr5:53026853-53026854 | Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
25 | rs13174659 | chr5:53026935-53026936 | Enhancers Flanking Active TSS | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
26 | rs533037783 | chr5:53026961-53026962 | Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
27 | rs256092 | chr5:53026986-53026987 | Enhancers Flanking Active TSS | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
28 | rs566308734 | chr5:53027017-53027018 | Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
29 | rs534101828 | chr5:53027032-53027033 | Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
30 | rs185672369 | chr5:53027046-53027047 | Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
31 | rs567548945 | chr5:53027133-53027134 | Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
32 | rs559677980 | chr5:53027175-53027176 | Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
33 | rs367842630 | chr5:53027255-53027256 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
34 | rs115852321 | chr5:53027333-53027334 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
35 | rs372311257 | chr5:53027339-53027340 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
36 | rs571438412 | chr5:53027389-53027390 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
37 | rs538721361 | chr5:53027448-53027449 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
38 | rs553767627 | chr5:53027457-53027458 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
39 | rs572311669 | chr5:53027537-53027538 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
40 | rs536319849 | chr5:53027539-53027540 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
41 | rs151333660 | chr5:53027545-53027546 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
42 | rs140445087 | chr5:53027546-53027547 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
43 | rs150413895 | chr5:53027573-53027574 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
44 | rs146565674 | chr5:53027588-53027589 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
45 | rs570965083 | chr5:53027590-53027591 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
46 | rs565449669 | chr5:53027638-53027639 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
47 | rs147216797 | chr5:53027641-53027642 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
48 | rs368689482 | chr5:53027642-53027643 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
49 | rs75954651 | chr5:53027643-53027644 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
50 | rs141301274 | chr5:53027671-53027672 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Basal cell lymphoma | 16317097 | CNVD |
Diffuse large b-cell lymphoma | 16317097 | CNVD |
Metanephric adenoma | 20802469 | CNVD |
Ewing''s sarcoma | 21437220 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Acute lymphoblastic leukemia | 17690704 | CNVD |
Gastrointestinal stromal cancer | 16982739 | CNVD |
Medulloblastoma | 21979893 | CNVD |
Phyllodes tumor | 17334353 | CNVD |
Malaria | 21533027 | CNVD |
Renal cell carcinoma | 19461508 | CNVD |
Colorectal cancer | 21645411 | CNVD |
Gastric cancer | 22152101 | CNVD |
Oesophago-gastric ulcer | 22152101 | CNVD |
Ovarian cancer | 21781307 | CNVD |
Breast cancer | 20668451 | CNVD |
Cancer | 20668451 | CNVD |
Lung cancer | 20668451 | CNVD |
Ovarian cancer | 20668451 | CNVD |
Pancreas cancer | 20668451 | CNVD |
Prostate cancer | 20668451 | CNVD |
Cancer | 20164919 | CNVD |
Acute lymphoblastic leukemia | 20435627 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Multiple myeloma | 17550852 | CNVD |
Thoracic aortic aneurysm | 21092924 | CNVD |
DNA damage stimulus | 22844521 | CNVD |
DNA repair | 22844521 | CNVD |
Breast cancer | 21785460 | CNVD |
Spinal muscular atrophy | 22422766 | CNVD |
Spinal muscular atrophy | 22558076 | CNVD |
Spinal muscular atrophy | 21320981 | CNVD |
Spinal muscular atrophy | 21762474 | CNVD |
Cancer | 16751803 | CNVD |
Autism | 22495311 | CNVD |
Intellectual disability | 22102821 | CNVD |
Prostate cancer | 21965145 | CNVD |
Cancer | 21183584 | CNVD |
Ovarian cancer | 20844748 | CNVD |
Myeloproliferative neoplasm | 20015882 | CNVD |
Breast cancer | 17603634 | CNVD |
Acute lymphoblastic leukemia | 20067559 | CNVD |
Melanoma | 18172304 | CNVD |
Glioma | 20126413 | CNVD |
Non-small cell lung cancer | 21829676 | CNVD |
Breast cancer | 22032731 | CNVD |
Esophageal cancer | 20955586 | CNVD |
Congenital anomalies of the kidney and urinary tract | 18694510 | CNVD |
Breast cancer | 17393978 | CNVD |
Cancer | 21359685 | CNVD |
adenomatous polyposis | 22470819 | CNVD |
Chronic lymphocytic leukemia | 21546498 | CNVD |
Acute myeloid leukemia | 20729466 | CNVD |
Cancer | 22429812 | CNVD |
Cancer | 21637783 | CNVD |
Colorectal cancer | 20709793 | CNVD |
Non-syndromic sensorineural hearing loss | 18471307 | CNVD |
Liposarcoma | 21253554 | CNVD |
Acute lymphoblastic leukemia | 21390130 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Breast cancer | 21264507 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Glioblastoma multiforme | 19960244 | CNVD |
Glioblastoma multiforme | 17387387 | CNVD |
Breast cancer | 21858162 | CNVD |
Hepatocellular carcinoma | 16750200 | CNVD |
Leukemia | 17361228 | CNVD |
Myelodysplastic syndrome | 18508791 | CNVD |
5q-syndrome | 17576883 | CNVD |
Gastric cancer | 17908304 | CNVD |
Lung cancer | 16740712 | CNVD |
Oral squamous cell carcinoma | 17134496 | CNVD |
Lung cancer | 18438408 | CNVD |
Urothelial carcinoma | 21177765 | CNVD |
Acute myeloid leukemia | 21251322 | CNVD |
Breast cancer | 21364760 | CNVD |
Oral cancer | 21386901 | CNVD |
Hodgkin''s lymphoma | 17606441 | CNVD |
Bladder cancer | 21909424 | CNVD |
Esophageal adenocarcinoma | 19417022 | CNVD |
Barrett''s syndrome | 19417022 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Myelofibrosis | 22110671 | CNVD |
Lung cancer | 21911935 | CNVD |
Breast cancer | 17133270 | CNVD |
Breast cancer | 19602461 | CNVD |
Acute lymphoblastic leukemia | 21339820 | CNVD |
Renal cell carcinoma | 18194544 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr5:53026200-53026800 | Weak transcription | Primary hematopoietic stem cells short term culture | blood |
2 | chr5:53026600-53026800 | Enhancers | Primary hematopoietic stem cells G-CSF-mobilized Female | -- |
3 | chr5:53026600-53028000 | Enhancers | Primary hematopoietic stem cells G-CSF-mobilized Male | -- |
4 | chr5:53026600-53028000 | Enhancers | HUVEC | blood vessel |
5 | chr5:53026800-53027200 | Flanking Active TSS | Primary hematopoietic stem cells G-CSF-mobilized Female | -- |
6 | chr5:53026800-53027400 | Enhancers | Primary B cells from peripheral blood | blood |
7 | chr5:53026800-53027600 | Enhancers | Primary hematopoietic stem cells | blood |
8 | chr5:53026800-53027800 | Enhancers | Primary hematopoietic stem cells short term culture | blood |
9 | chr5:53027000-53027400 | Enhancers | Primary neutrophils fromperipheralblood | blood |
10 | chr5:53027000-53027600 | Enhancers | Primary B cells from cord blood | blood |
11 | chr5:53027200-53028200 | Enhancers | Primary hematopoietic stem cells G-CSF-mobilized Female | -- |
12 | chr5:53029800-53030000 | Enhancers | Primary hematopoietic stem cells G-CSF-mobilized Male | -- |
13 | chr5:53034800-53035400 | Enhancers | Breast variant Human Mammary Epithelial Cells (vHMEC) | Breast |
14 | chr5:53034800-53035400 | Enhancers | Foreskin Keratinocyte Primary Cells skin03 | Skin |
15 | chr5:53034800-53035600 | Enhancers | HMEC | breast |
16 | chr5:53035000-53035400 | Enhancers | Foreskin Keratinocyte Primary Cells skin02 | Skin |
17 | chr5:53035000-53035400 | Enhancers | Esophagus | oesophagus |
18 | chr5:53041800-53042000 | Enhancers | iPS DF 19.11 Cell Line | embryonic stem cell |
19 | chr5:53042000-53046600 | Weak transcription | iPS DF 19.11 Cell Line | embryonic stem cell |
20 | chr5:53046600-53046800 | ZNF genes & repeats | iPS DF 19.11 Cell Line | embryonic stem cell |
21 | chr5:53046800-53052600 | Weak transcription | iPS DF 19.11 Cell Line | embryonic stem cell |
22 | chr5:53048000-53048400 | ZNF genes & repeats | hESC Derived CD56+ Ectoderm Cultured Cells | ES cell derived |
23 | chr5:53053000-53055800 | Weak transcription | Right Atrium | heart |